• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » BioSphere’s Q4 sales spike 15 percent on liver cancer treatment

BioSphere’s Q4 sales spike 15 percent on liver cancer treatment

February 11, 2010 By MassDevice staff

BioSphere Medical Inc. (NSDQ:BSMD) managed to cut its losses in half during 2009, ending the year with a 7 percent sales increase.

The Rockland, Mass.-based microsphere maker reported a net loss of $293,000 on $8.4 million in sales during the three months ended Dec. 31, 2009, compared to a $1.7 million loss on $7.2 million in sales for the same period in 2008.

For the full year, BioSphere halved its losses, reporting a $3.2 million loss on $31 million in sales, compared to a $6 million loss on $29 million in revenues during 2008. BioSphere said it significantly cut expenses by turning its marketing efforts from a national campaign to a more targeted, local approach.

The revenue increase was mostly the result of a nearly 70 percent increase in sales of products used by radiologists to treat liver cancer, which BioSphere claimed was a direct result of “publications and podium presentations by thought leaders of the results of their independent work in the use of our embolics.”

The company said it sees a fertile market for its products in the treatment of liver cancer. BioSphere is working with the Food & Drug Administration to secure an investigational device exemption for a 200-patient pivotal study using doxorubicin-loaded QuadraSpheres to treat primary liver cancer. The company estimates that there are more than 600,000 cases of liver cancer across the globe.

Sales of the company’s embolics, used to treat uterine fibroids, also saw a 5 percent increase during the fourth quarter, mostly on the strength of sales outside the United States.

In other news, BioSphere revealed that two of its largest institutional shareholders have added to their stakes in the firm over the past year.

In filings with the federal Securities & Exchange Commission, Boston-based private equity fund Portolan Capital Management LLC pushed its stake to more than 1.2 million shares, or nearly 7 percent of BioSphere’s total. Portolan reported last year that it owned just more than 900,000 shares of BioSphere stock.

And Boston-based Clough Capital Partners LP also disclosed a slightly larger stake in the company, increasing its ownership by about 100,000 shares to 1.4 million, good for a nearly 8 percent stake in BioSphere.

Filed Under: Biotech, Business/Financial News, Gynecological, MassDevice Earnings Roundup, News Well, Oncology Tagged With: BioSphere Medical Inc.

More recent news

  • Neuronetics names Steven Pfanstiel chief financial officer
  • Medtronic to distribute Future Medical’s peripheral guidewires
  • AtriCure completes enrollment in stroke prevention trial
  • GT Medical raises $53M to support brain tumor treatment
  • Imperative Care, Proximie partner to develop surgical robot to treat stroke

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy